BRAF anticorps

N° du produit ABIN968991

Détail du produit anti-BRAF anticorps

Antigène: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp BRAF est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunocytochemistry (ICC)

Fonction: BRAF Antibody

Purification: Ascitic fluid

Immunogène: Purified recombinant fragment of human BRAF expressed in E. Coli.

Clone: 1H12

Isotype: IgG1

Information d'application

Indications d'application:

ELISA: 1/10000

ICC: 1/200 - 1/1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Références pour anticorps anti-BRAF (ABIN968991)

Di Nicolantonio, Martini, Molinari, Sartore-Bianchi, Arena, Saletti, De Dosso, Mazzucchelli, Frattini, Siena, Bardelli: "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer." dans: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 26, Issue 35, pp. 5705-12, (2008) (PubMed).

Riesco-Eizaguirre, Gutiérrez-Martínez, García-Cabezas, Nistal, Santisteban: "The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane." dans: Endocrine-related cancer, Vol. 13, Issue 1, pp. 257-69, (2006) (PubMed).

Détails sur BRAF

Antigène: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Autre désignation: BRAF (BRAF Produits)

Synonymes: anticorps B-RAF1, anticorps BRAF1, anticorps NS7, anticorps RAFB1, anticorps C-RMIL, anticorps RMIL, anticorps B-Raf, anticorps braf1, anticorps rafb1, anticorps b-raf1, anticorps sierrabraf, anticorps BRAF, anticorps 9930012E13Rik, anticorps AA120551, anticorps AA387315, anticorps AA473386, anticorps B-raf, anticorps Braf-2, anticorps Braf2, anticorps C230098H17, anticorps C87398, anticorps D6Ertd631e, anticorps braf, anticorps fc48g01, anticorps wu:fc48g01, anticorps B-Raf proto-oncogene, serine/threonine kinase, anticorps B-Raf proto-oncogene, serine/threonine kinase S homeolog, anticorps Braf transforming gene, anticorps si:dkey-222f8.3, anticorps BRAF, anticorps Braf, anticorps braf.S, anticorps braf, anticorps si:dkey-222f8.3

Sujet:

Description: BRAF: v-raf murine sarcoma viral oncogene homolog B1, also known as BRAF1, RAFB1, B-RAF1, FLJ95109. Entrez Protein NP_004324. It is the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. B-Raf contains three consensus Akt phosphorylationsites (Ser364, Ser428, and Thr439). B-Raf is a key regulatory molecule of the mitogen-activated protein kinase kinase (MEK), it has a long amino-terminal region,the region is essential for homo-dimerization of B-Raf and hetero-dimerization of B-Raf and c-Raf at the plasma membrane, followed by phosphorylation of Thr118 in the amino-terminal B-Raf-specific region. Notably, in calcium ionophore-stimulated HeLa cells, B-Raf could propagate signals to MEK under the basal level of GTP-Ras. Expression of Raf-B is highly restricted with highestlevels in the cerebrum and testes and defects in braf are involved in a wide range of cancers. The BRAF gene mutation is frequently detected in papillary thyroid carcinoma,melanocytic nevi, primary cutaneous melanomas and colorectal cancers.

Aliases: BRAF1, RAFB1, B-RAF1, FLJ95109

Poids moléculaire: 87kDa

ID gène: 673

HGNC: 673

UniProt: P15056

Pathways: Signalisation MAPK, Signalisation RTK, Neurotrophin Signaling Pathway, Ribonucleoprotein Complex Subunit Organization, Hepatitis C, Autophagy